WaveBreak

The company's core technology focuses on a drug discovery platform designed to target and inhibit the transient, toxic protein intermediates, known as oligomers, which are understood to be a primary cause of neurotoxicity in protein misfolding diseases. This approach differs from conventional methods by focusing on the chemical kinetics of the protein misfolding process, aiming to block the generation of these harmful oligomers at their source. This strategy addresses the challenge that these oligomers are highly transient and difficult to target with traditional drug discovery techniques.

WaveBreak is advancing lead programs targeting α-synuclein for Parkinson's disease and amyloid-β for Alzheimer's disease. The company operates from headquarters in Boston, MA, and maintains a presence in Cambridge, UK. It has raised significant funding through multiple rounds, including a Series A round, to advance its pipeline and platform. The business model is centered on the discovery, development, and eventual commercialization of its novel therapeutics to address substantial unmet medical needs in the neurodegenerative space.